Capivasertib (Truqap)

Key Messages

• Note: Due an administrative error, the patient input submission from Breast Cancer Canada was mistakenly omitted from the review and is not reflected in the review reports or the recommendation document. CDA-AMC appreciates the effort required to compile patient group input. The input from Breast Cancer Canada has been included in the summary document to ensure that their contributions to the reimbursement review process are reflected in final documentation and their valuable input is available to our health system partners and other interested parties. 

• Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.

• The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses capivasertib (Truqap) 400 mg (2 tablets of 200 mg each) taken orally twice daily for 4 days followed by 3 days off treatment in combination with fulvestrant 500 mg, administered intramuscularly on days 1, 15, and 29, then monthly thereafter.
• Indication: Capivasertib is indicated in combination with fulvestrant for the treatment of adult females with hormone receptor–positive, human epidermal growth factor receptor 2–negative, locally advanced or metastatic breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing, adjuvant therapy.